USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
2014 Life Sciences Outlook in Turkey
2014 Life Sciences Outlook in Turkey
Rapid Economic Development and Healthcare Reforms Set the Stage for the Future
RELEASE DATE
04-Nov-2014
04-Nov-2014
REGION
North America
North America
Research Code: MA8D-01-00-00-00
SKU: LS00104-NA-MR_16945
$2,450.00
Special Price $1,837.50 save 25 %
In stock
SKU
LS00104-NA-MR_16945
Description
The Turkish pharmaceuticals segment is the 14th largest worldwide and the 6th largest in Europe, valued at $14.04 billion in 2013 and projected to grow at a CAGR of 9.1% from 2013 to 2018. Growth is driven by expanding public insurance, modernisation, prevalence of chronic diseases, increasing health awareness, and affluence. Market segmentation is based on products (e.g., over-the-counter, generic, and patented drugs) and therapeutic areas (e.g., antibiotics, anti-rheumatics, cardiovascular, analgesics, oncology, cough preparations, and central nervous system). The study provides a macroeconomic overview of Turkey’s mergers and acquisitions/investment trends, regulatory environment, revenue forecasts, key trends, and companies to watch.
Table of Contents
Executive Summary
Executive Summary (continued)
Study Scope
Study Scope—Segmentation of the Pharmaceutical Industry
Study Scope—Segmentation of Pharmaceutical Industry (continued)
Study Scope—Segmentation of Pharmaceutical Industry (continued)
Total Life Sciences Market—Segmentation
Turkey Life Sciences Market—Snapshot
State of Turkey Life Sciences in 2012 and 2013
Top 3 Growth Sectors
Accelerating Trends Make Their Mark in Turkey
MNCs to Watch—High Tech, M&A, and Value-based Products to Capitalize on First-mover Advantage
Domestic Companies to Watch—Pioneers of R&D Paving the Way for Innovation in Turkey
Medical Tourism Market—Still Attractive
Strategic Action Plan for the Pharmaceuticals Segment– Current Ranking and Vision 2023
Turkey—A Rapid-growing Economy
History of the Turkish Pharmaceutical Industry
HTP—Overview
HTP—Major Reforms 2003 to 2010
HTP—Strategic Plan 2010 to 2014
Impact of the HTP—Universal Health Insurance
Impact of the HTP—FP Services
Impact of the HTP—Management of Diseases and Promotion of Health
HTP—Regional Development of Infrastructure
Impact of the HTP—Development of Health Infrastructure
Impact of the HTP—Increased Healthcare Spending
Impact of the HTP—Increased Healthcare Spending (continued)
Impact of the HTP—Increased Pharmaceutical Spending
Impact of the HTP—Tapering Out-of-pocket Payment
Demographics—Aging Population
Demographics—Young Workforce and Employment
Demographics—Key Health Indicators and Top Causes of Death
Disease Burden—Prevalence Rates of Top Diseases
Disease Burden—Incidences of Top Infectious Diseases
Disease Burden—Cancer Incidence Rates
Pharmaceuticals Segment Analysis
Pharmaceuticals Segment—Revenue Forecast
Pharmaceuticals Segment—Percent Revenue Forecast by Product
Pharmaceuticals Segment—Percent Revenue Forecast by Therapeutic Area
Growth Opportunities in the Pharmaceuticals Segment
Challenges in the Pharmaceuticals Segment
Pharmaceuticals Segment—SWOT Analysis
Turkey—A Lucrative Hub for Foreign Investors
Big Pharma Heavy Investment Plans in Turkey
M&A Activity Intensifies in Turkey
M&A Activity Intensifies in Turkey (continued)
Turkey Clinical Research Attractiveness Index
Incentive Programs to Foster R&D and Innovation in Turkey
R&D Incentive Programs—TUBITAK-TEYDEB
R&D Incentive Programs—TDZ
R&D Incentive Programs—SAN-TEZSAN-TEZ
Key Research Centres Active in Pharmaceutical R&D
Key International Companies Active in Pharmaceutical R&D
Key International Companies Active in Pharmaceutical R&D (continued)
Key Local Companies Active in Pharmaceutical R&D
Pharmaceutical Production—Export-Import Ratio
Pharmaceutical Raw Materials Production—Key Stakeholders
Pharmaceutical Raw Materials Production—Key Stakeholders (continued)
Pharmaceutical Raw Materials Production—Key Stakeholders (continued)
Pharmaceutical Production Capacity Utilisation
Top 10 Pharmaceutical Companies in Turkey
Pharmaceutical Production—Key Stakeholders
Pharmaceutical Wholesale Market—Turkey
Pharmaceutical Wholesale Market—Key Stakeholders
Pharmaceutical Retail Market—Turkey
Key Regulatory Bodies that Govern the Turkish Pharmaceutical Industry
Key Regulatory Bodies that Govern the Turkish Pharmaceutical Industry (continued)
Key Regulatory Bodies that Govern the Turkish Pharmaceutical Industry (continued)
Turkey’s SSI (SGK) Healthcare Coverage
Pharmaceutical Pricing Regulation in Turkey
Pharmaceutical Reimbursement Regulation in Turkey
Pharmaceuticals Segment—Reimbursements in Turkey
Pharmaceutical Licensing Procedure in Turkey
Pharmaceutical Licensing Regulation
Clinical Diagnostics Segment Analysis
Clinical Diagnostics Segment—Revenue Forecast
Clinical Diagnostics Segment—Revenue Forecast by Sub-segment
Growth Opportunities in the Clinical Diagnostics Segment
Challenges in the Clinical Diagnostics Segment
Turkey—A Developing Regional Life Sciences Capital
Free Healthcare Zones—A Strategic Initiative Propelled by the Growing Medical Tourism Industry in Turkey
MoH—Strategic Plan 2013 to 2017: Improvement of Public Health
Ministry of Science, Industry, and Technology—Strategic Goals
The Government’s 2023 Vision
The Last Word—3 Big Predictions
Legal Disclaimer
The Frost & Sullivan Story
Value Proposition
Global Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Our Blue Ocean Strategy
Popular Topics
The diabetes diagnostics markets in the United States and Europe have been in a mature stage for many years. Growth is sustained due to the high prevalence of diabetes in both regions. The segments covered in the study are self-monitoring of blood glucose (SMBG), point-of-care testing (POCT), and lab-based HbA1c testing. The emerging market of non-invasive technologies is disrupting this market space as it reduces patient pain points while providing accurate and sensitive results. Due to more hospital-centric care in the EU region, the POCT segment here experiences stronger growth than in the United States. POCT has the potential to grow the fastest due to its efficient, cost-effective solution and increasing adoption by physicians. --BEGIN PROMO-- 
| No Index | No |
|---|---|
| Podcast | No |
| Author | Aiswariya Chidambaram |
| WIP Number | MA8D-01-00-00-00 |
| Keyword 1 | Life Sciences Outlook |
| Keyword 2 | Life Sciences in Turkey |
| Is Prebook | No |